The capstone to this series, for anyone who has collected diagnoses without ever being shown how they connect.
If you’ve been reading this series from the beginning, something has probably been building in the back of your mind.
The cholesterol article mentioned insulin resistance. The insulin resistance article mentioned blood pressure. The blood pressure article mentioned the kidney. The diabetes article referenced the liver. The obesity article ran through almost everything. The hormones article connected to the thyroid, which connected to sleep, which connected to depression, which connected back to inflammation, which connects to all of it.
You may have started to notice that these are not separate problems happening independently in different organs. They are the same problem expressing itself in different places at different stages of the same progression.
Medicine named them separately because it studies and treats them through specialty silos: cardiology, nephrology, endocrinology, rheumatology, psychiatry. Each specialty has its guidelines, its medications, its monitoring protocols. This is not wrong. The specialization has produced genuinely good clinical science. But it has also created a gap at the center, a space where the connections between conditions live, where the earlier stages of a long progression quietly build, where the person sitting in front of the doctor is the only one seeing the whole picture.
In October 2023, the American Heart Association did something that hadn’t been done before. They formally named that gap. They published a Presidential Advisory in Circulation introducing the concept of Cardiovascular-Kidney-Metabolic syndrome, or CKM syndrome, a unified framework that describes the interplay between obesity, metabolic dysfunction, chronic kidney disease, and cardiovascular disease as a single, staged, progressive system rather than a collection of separate conditions [1].
This is the capstone of this series. Not because it’s the most dramatic diagnosis we’ve covered, but because it’s the frame that makes all the others make sense. If you have two or more of the conditions covered in this series, or if you’ve been told you’re “borderline” on several things without anyone connecting the dots, this article is for you.
This is the opening of a longer article.
The full piece — the mechanisms, the labs to ask for, and what to do about it — is free to read on our newsletter.
Sources & Research
Every claim in this article is grounded in peer-reviewed research. DOI links open the original studies.
Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606–1635. doi:10.1161/CIR.0000000000001184
Gajjar A, Raju AK, Gajjar A, et al. SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular-kidney-metabolic syndrome. Biomedicines. 2025;13(8):1924. doi:10.3390/biomedicines13081924
Theodorakis N, Nikolaou M. From cardiovascular-kidney-metabolic syndrome to cardiovascular-renal-hepatic-metabolic syndrome: proposing an expanded framework. Biomolecules. 2025;15(2):213. doi:10.3390/biom15020213
Laffin LJ, Bakris GL. Cardiovascular-kidney-metabolic syndrome: prevalence, risks, disease trajectories, and early-stage management. American Journal of Physiology: Cell Physiology. 2025. doi:10.1152/ajpcell.00499.2025
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. 2024;391(2):109–121. doi:10.1056/NEJMoa2403347
